Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC.

Trial Profile

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Renal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors SFJ Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2018.
    • 11 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Jun 2015 Planned number of patients changed from 592 to 700 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top